Amphotericin B: Side Effects, Uses & Monitoring
Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients.
- Data source
- FDA labeling via NIH DailyMed (label 2b2f3ff5…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
| Adverse reaction (as reported in labeling) | Reported frequency* |
|---|---|
| Total number of patients | 166% |
| Chills/rigors | 89.7% |
| Chills | 75.9% |
| Hypokalemia | 50.6% |
| Anemia | 47.9% |
| Vomiting | 43.9% |
| Creatinine increased | 42.2% |
| Nausea | 39.7% |
| Bun increased | 31.1% |
| Diarrhea | 30.3% |
| Dyspnea | 29.1% |
| Hyperglycemia | 27.9% |
| Hypomagnesemia | 25.6% |
| Phlebitis | 25.3% |
| Rash | 24.8% |
| Alkaline phosphatase increased | 22.2% |
| Abdominal pain | 21.8% |
| Cough increased | 21.8% |
| Hypotension | 21.5% |
| Tachycardia | 20.9% |
*Highest percentage reported for the active moiety across placebo-controlled trial tables in current FDA labeling. Values reflect trial reporting, not your individual risk.
Labeled uses (from FDA prescribing information)
Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication. DESCRIPTION OF CLINICAL STUDIES Eleven clinical studies supporting the efficacy and safety of amphotericin B liposome for injection were conducted. This clinical program included both controlled and uncontrolled studies. These studies, which involved 2,171 patients, included patients with confirmed systemic my…
Conditions associated with Amphotericin B in labeling
Frequently Asked Questions
What is Amphotericin B used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Amphotericin B?
The table above shows adverse reactions and the highest frequencies reported in placebo-controlled trials summarized in current FDA labeling for Amphotericin B. Individual risk varies.
Does Amphotericin B require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Amphotericin B.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.